Results 41 to 50 of about 176 (130)

Priapism as the first manifestation in chronic myeloid leukemia: A case report and focused review of literature

open access: yesClinical Case Reports, 2021
We report the case of a patient who was initially presented with ischemic priapism to the emergency department. He was treated with adrenaline intracavernous injections and aspiration with irrigation of the corpora cavernosa and distal shunt.
Claudia Lucia Sossa Melo   +6 more
doaj   +1 more source

Real‐World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety‐Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024

open access: yesCancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background While overall survival for chronic myeloid leukemia (CML) at 5 years now exceeds 90% with modern tyrosine kinase inhibitor (TKI) therapies, disparities in management and outcomes persist among underserved populations. This study describes TKI treatment patterns and outcomes in a predominantly Hispanic, underserved CML cohort treated
Dominick Zheng   +4 more
wiley   +1 more source

Polycythemia vera masked due to severe iron deficiency anemia

open access: yesHematology/Oncology and Stem Cell Therapy, 2018
Polycythemia vera is one of the chronic myeloproliferative diseases and very few patients present with its actual clinical manifestations. The most common findings are increased red cell mass and an increased leukocyte count with decreased erythropoietin.
Shweta Kambali, Asma Taj
doaj   +1 more source

Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo, 2010
Introduction Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia.
Ćojbašić Irena   +1 more
doaj   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

open access: yesVeterinary and Comparative Oncology, Volume 24, Issue 3, Page 532-544, September 2026.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson   +5 more
wiley   +1 more source

Integrin α5β1 in pancreatic ductal adenocarcinoma: Tumour‒stroma crosstalk, hypoxia and therapeutic targeting

open access: yesClinical and Translational Medicine, Volume 16, Issue 8, August 2026.
ITGA5/integrin α5β1 promotes PDAC progression by integrating fibronectin‐dependent adhesion, hypoxia‐associated ECM remodelling, pancreatic stellate cell/cancer‐associated fibroblast activation, desmoplasia and tumour‒stroma crosstalk. These processes contribute to impaired drug delivery and therapeutic resistance.
Chenzhe Ma, Yingying Wang, Yumin Li
wiley   +1 more source

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? [PDF]

open access: yesReviews in Clinical Medicine, 2015
Chronic myelogenous leukemia is a myeloproliferative disorder presenting with anemia, elevated blood granulocytosis and the presence of immature granulocytes, basophilia, frequently thrombocytosis and spleen enlargement.
Hossein Rahimi   +2 more
doaj   +3 more sources

Anaphylactic transfusion reaction to group B platelets related to alpha‐gal syndrome: A case report

open access: yesTransfusion, Volume 66, Issue 8, Page 1690-1693, August 2026.
Abstract Background Alpha‐gal syndrome (AGS), a distinct form of IgE‐mediated hypersensitivity to the carbohydrate galactose‐α‐1,3‐galactose (α‐Gal), typically occurs after repeated tick bites and leads to allergic reactions after ingestion of mammalian meat.
Oscar Andre Hinojosa   +2 more
wiley   +1 more source

Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients [PDF]

open access: yesBlood, 1993
Abstract We report here the results of polymerase chain reaction (PCR) for bcr- abl transcript and clinical details derived from 64 chronic myelogenous leukemia (CML) patients after allogeneic bone marrow transplantation (BMT). A total of 139 samples (2 to 220 weeks after BMT) were analyzed and bcr-abl transcript was detected in 99 ...
K, Miyamura   +9 more
openaire   +3 more sources

Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy [PDF]

open access: yesVojnosanitetski Pregled, 2012
Background/Aim. Introducing tyrosine kinase inhibitors (TKIs) has essentially changed curative approach, to be precise, clearly improved treatment efficacy for chronic myeloid leukemia (CML).
Stamatović Dragana   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy